A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects With Mild to Moderate Ulcerative Colitis.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs SRT 2104 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sirtris
- 10 Jun 2017 Biomarkers information updated
- 24 Feb 2012 Actual initiation date (Feb 2012) added as reported by ClinicalTrials.gov.
- 24 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.